Genovis (Q3 initial take): Solid beat across the board - Redeye

Genovis (Q3 initial take): Solid beat across the board - Redeye

A record quarter in Genomics drove Q3 2026 sales of SEK36.9m, 5% above our estimate, and lifted EBITDA 23% above our forecast. The result confirms improving underlying demand and the earnings leverage of the broadened platform.

Länk till analysen i sin helhet: https://www.redeye.se/research/1189710/genovis-q3-initial-take-solid-beat-across-the-board?utm_source=finwire&utm_medium=RSS